Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | AGXT | P21549 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 5/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28768145 | 0.81 | LOXL2 (0.58) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL30511855 | 0.81 | LOXL2 (0.58) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL112634 | 0.81 | LOXL2 (0.58) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL859678 | 0.81 | LOXL2 (0.58) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL28076067 | 0.79 | LOXL2 (0.56) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL3264177 | 0.78 | LOXL2 (0.59) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL4386951 | 0.78 | LOXL2 (0.55) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL5793787 | 0.78 | LOXL2 (0.55) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL28311732 | 0.78 | LOXL2 (0.55) | LOXL2AGXTHTR2BHTR1ACYP2A6 | |
| SCHEMBL119196 | 0.78 | LOXL2 (0.64) | LOXL2AGXTHTR2BHTR1ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-0682516-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5455265-A | For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others | ALLERGAN, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994017796-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | PPARD, PPARG, PPARA | LOXL2 3288/4885AGXT 3280/4885HTR2B 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.